REDX is a clinical-stage R&D company focused on drugs targeting oncology and fibrotic disease. 2018 was a year that reset the benchmarks – new management team, restructured organisation focused on two therapeutic areas, and a clean balance sheet. 2019 will be characterised by a number of major milestones, including the recent restart of the Phase I/IIa trial with RXC004 with a revised protocol, and we note that RXC006 has been nominated as the first development candidate in the anti-fibrotic programme. Meanwhile, operating costs have been reduced while management considers all options available to strengthen its balance sheet.
If you'd like to be introduced to the team at Redx Pharma, get in touch.Request a meeting